Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (noting the input metadata reference to "Cypherpunk Technologies Inc." appears to be an error, as the filing text explicitly identifies Leap Therapeutics, Inc.) on January 3, 2020, with a signature date of January 7, 2020. The report details a material definitive agreement involving a private placement transaction and related corporate actions to address Nasdaq listing compliance.
Key Financial Metrics and Transaction Details
- Transaction Proceeds: The Company entered into a Securities Purchase Agreement to raise aggregate gross proceeds of approximately $27 million.
- Securities Issued:
- 1,421,801 shares of Series A Preferred Stock at $10.54 per share.
- 1,137,442 shares of Series B Preferred Stock at $10.55 per share.
- 1 share of Special Voting Stock.
- Conversion Terms: Subject to stockholder approval, the preferred stock will convert into Common Stock and/or Pre-Funded Warrants. Coverage Warrants were issued with an exercise price of $2.11 per share.
- Placement Agent Fees: Raymond James & Associates, Inc. received a fee representing a blended rate of 3.4074% of gross proceeds.
- Stockholders' Equity: As of the September 30, 2019 quarter, stockholders' equity was reported at $5,562,000, which was below the Nasdaq minimum requirement of $10,000,000.
Material Changes and Corporate Actions
The primary material change is the execution of the private placement to raise capital. Concurrently, the Company filed Certificates of Designation for the Series A and Series B Preferred Stock and Special Voting Stock with the Delaware Secretary of State on January 7, 2020. The Company also entered into Voting Agreements with existing stockholders to secure approval for the transaction and Registration Rights Agreements with purchasers.
Outlook, Risks, and Contingencies
- Nasdaq Compliance: The transaction was executed to regain compliance with Nasdaq Listing Rule 5450(b)(1)(A) regarding the $10 million minimum stockholders' equity requirement. While the Company believes it has regained compliance, Nasdaq will continue to monitor the situation, and delisting remains a risk if compliance is not evidenced in the next periodic report.
- Stockholder Approval: The conversion of preferred stock into common stock and the issuance of warrants are contingent upon stockholder approval. The Company must call a meeting within 90 days to vote on increasing authorized shares to 250 million and approving the issuance.
- Forward-Looking Risks: There is no assurance the transactions will be completed on the described terms or at all, primarily due to the risk of failing to obtain required stockholder approval.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required to approve the conversion of preferred stock and the increase in authorized shares.
- Confirm the Company's continued compliance with Nasdaq listing requirements in subsequent periodic reports.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and limitations.
- Monitor the dilution impact resulting from the conversion of preferred stock and the exercise of coverage warrants at the $2.11 strike price.